Back in October 2014, Profectus BioSciences scored $9.5 million in Department of Defense funding to manufacture its trivalent vaccine to protect against Ebola and Marburg viruses. Now, the Baltimore-based biotech is taking its Ebola candidate to Phase I trials.
As the Ebola outbreak continues with deadly momentum, drugmakers are working at lightning speed to develop a vaccine.
Baltimore-based Profectus Biosciences has inoculated its first patient in a Phase I trial of its multi-antigen DNA HIV vaccine. The study will monitor 60 HIV patients who are on stable